Citalopram in the treatment of depression
and other potential uses in psychiatry
by
Tan JY, Levin GM
Capital District Psychiatric Center,
Albany, New York, USA.
Pharmacotherapy 1999 Jun; 19(6):675-89

ABSTRACT

During the past decade, treatment options for depression have increased with the introduction of new agents. Older agents, such as tricyclic antidepressants and monoamine oxidase inhibitors, increase noradrenergic and serotonergic neurotransmission. Attempts to separate antidepressant effects from adverse effects led to the development of selective serotonin reuptake inhibitors (SSRIs). Citalopram is the newest SSRI to be marketed in the United States. Of all SSRIs on the market, it is the most selective for serotonin reuptake pump. Its efficacy in treating depression was evident in both placebo-controlled and comparator trials. In addition, citalopram was studied in the treatment of other psychiatric disorders. The agent has less inhibition of cytochrome P450 enzymes than other SSRIs, possibly giving it a lower potential for drug interactions.

TCAs
SSRIs
MAOIs
Options
Serotonin
Escitalopram
SSRI spectrum
SSRI mechanisms
Future anxiolytics
Citalopram and OCD
21C antidepressants
Citalopram: structure
2 years on citalopram
Citalopram for depression
Citalopram and bipolar disorder
Citalopram and depression: trials
Citalopram: oral versus intravenous
The monoamine theory of depression
Citalopram for adolescents with major depression
Citalopram (Cipramil, Celexa) plus methylphenidate (Ritalin)

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family